Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
Lixisenatide bij vroege Parkinson: minder progressie van motorische beperkingen
jun 2024 | Bewegingsstoornissen